Despite the pivotal role of EGFR signaling, current international guidelines (ESGO, NCCN, ASCO, FIGO, ESMO, and others) for recurrent cervical cancer primarily recommend platinum-based chemotherapy, bevacizumab, and immunotherapy, without incorporating EGFR inhibitors [8]. This evidence concerns the gene EGFR and cervical carcinoma.